Abstract: The present invention includes: an identification code generation unit that generates, from information of a company code including a first code that uniquely identifies a management target in a part of a company in the part of the company and a second code that identifies the part of the company, an identification code including a history of the management target; a hash processing unit that hashes the identification code generated by the identification code generation unit according to a hash function and converts the hashed identification code into a meaningless code; and a reference code generation unit that generates a reference code unified for the entire company based on the meaningless code converted by the hash processing unit.

Abstract: To effectively enhance the operation efficiency of an autonomous mobile robot, an autonomous mobile robot control system includes a processor and a plurality of environmental cameras. The processor estimates a moving route of each of a plurality of moving bodies on the basis of characteristics of each of the plurality of moving bodies and sets a subset of the plurality of moving bodies whose moving routes overlap among the detected moving bodies as avoidance processing target moving bodies. The processor generates an avoidance procedure for the avoidance processing target moving bodies so the motion of the avoidance processing target moving bodies does not interfere with the motion of other avoidance target moving bodies.

Abstract: A solid-liquid boundary detection device 20 is a device for detecting a boundary 141 between a solid and a liquid in a test tube 14, and includes a surface illumination 21, an imaging unit 22, and a boundary detection processor 31. The surface illumination 21 illuminates the test tube 14 from outside. The imaging unit 22 is arranged on an opposite side of the test tube 14 from the surface illumination 21, and captures an image including the boundary 141. The boundary detection processor 31 detects the boundary 141 from the image captured by the imaging unit 22.

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).

Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: A flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, aluminum hydroxide, and a triazine ring containing hindered amine compound. With respect to 100 parts by mass of the polyolefin resin, the silicone compound is blended in an amount of the range 0.5 to 10 parts by mass, the fatty acid containing compound is blended in an amount of the range 0.5 to 20 parts by mass, the aluminum hydroxide is blended in an amount of the range 1 to 60 parts by mass, and the triazine ring containing hindered amine compound is blended in an amount of the range 0.05 to 8 parts by mass or less. The triazine ring containing hindered amine compound may include an oxygen atom.

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.

Abstract: A flame retardant resin composition comprises a polyolefin resin, calcium carbonate particles blended at a ratio of 5 pts. mass to 80 pts. mass, aluminum hydroxide blended at a ratio of 50 pts. mass to 125 pts. mass, a silicone-based compound blended at a ratio of more than 1 pt. mass and 10 pts. mass or less, a fatty acid-containing compound blended at a ratio of 3 pts. mass to 20 pts. mass, and a zinc-containing inorganic compound blended at a ratio of 1 pt. mass to 7 pts. mass, all relative to 100 pts. mass of the polyolefin resin. In the flame retardant resin composition, the calcium carbonate particles and the aluminum hydroxide are blended in total at a ratio of 55 pts. mass to 130 pts. mass relative to 100 pts. mass of the polyolefin resin.

Abstract: Disclosed is a flame retardant resin composition comprising: a polyolefin resin; a silicone-based compound blended at a ratio of 3 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin; calcium carbonate blended at a ratio of 10 parts by mass or more and less than 100 parts by mass relative to 100 parts by mass of the polyolefin resin; and aluminum hydroxide blended at a ratio of 5 parts by mass or more and 60 parts by mass or less relative to 100 parts by mass of the polyolefin resin.

Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).

Abstract: A flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, aluminum hydroxide, and a triazine ring containing hindered amine compound. With respect to 100 parts by mass of the polyolefin resin, the silicone compound is blended in an amount of the range 0.5 to 10 parts by mass, the fatty acid containing compound is blended in an amount of the range 0.5 to 20 parts by mass, the aluminum hydroxide is blended in an amount of the range 1 to 60 parts by mass, and the triazine ring containing hindered amine compound is blended in an amount of the range 0.05 to 8 parts by mass or less. The triazine ring containing hindered amine compound may include an oxygen atom.

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: Disclosed is a flame retardant resin composition in which relative to 100 parts by mass of the base resin, a silicone based compound is blended at a ratio of 0.1 to 10 parts by mass a fatty acid metal salt is blended at a ratio of 0.1 to 20 parts by mass, a flame retardant agent is blended at a ratio of 5 to 200 parts by mass, a hindered phenol based compound is blended at a ratio of 0.05 to 10 parts by mass, and a hindered amine based compound is blended at a ratio of 0.05 to 10 parts by mass. The hindered amine based compound has a group represented by the following formula (1). (R1 represents an alkyl or alkoxy group having 1 to 30 carbon atoms, and R2 to R5 each independently represent an alkyl group having 1 to 6 carbon atoms).